Radionuclide Supply
Tb-161
TERBIUM-161 NCA
Next-Generation Radionuclide for Precision Oncology
Non-Carrier added (NCA) lanthanide Terbium-161(Tb-161) is is produced by neutron activation of Gadolinium-160 and offers a unique decay profile, setting new standards for targeted radioligand therapy (RLT).
Radioligand Therapy
Using PSMA and SST analogues, Terbium-161 has shown excellent bioequivalence presenting a biodistribution comparable to the currently used radiolanthanides. Additionally, the 16-fold increase in Auger and conversion electrons is expected to improve the cellular absorbed dose up to 3-fold compared to currently used radiolanthanides, while allowing for treatment of both primary and undetectable (micro) metastasis, improving the overall disease control.
Imaging Optimized
Allowing optimization of the SPECT reconstruction parameters, Terbium-161 may provide for higher spatial resolution SPECT imaging, leading to the detection of smaller lesions that provides input for a further optimized treatment plan.
Radiation Safety
Terbium-161 provides for an immediate decrease in dose rate allowing for a significant improvement in general radiation safety. This optimization of radiation safety may extend current treatment room capacity for Radioligand Therapy. The non-carrier added (NCA) product allows optimal control of radioactive waste flow with reduced decay time in local storage.
Contact us
As an Asia distribution hub based in Taiwan, Primo is committed to providing efficient logistics services, ensuring the rapid delivery of radioisotopes to multiple countries across the region. This minimizes transport time and cold chain risks, preserving the product’s integrity and potency.